83 related articles for article (PubMed ID: 29600976)
1. Impact of endostatin gene therapy on myeloid-derived suppressor cells from a metastatic renal cell carcinoma.
Chaves KC; Costa EM; Teixeira LF; Bellini MH
Exp Oncol; 2018 Mar; 40(1):24-32. PubMed ID: 29600976
[TBL] [Abstract][Full Text] [Related]
2. Fibronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy.
Chaves KC; Turaça LT; Pesquero JB; Mennecier G; Dagli ML; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2012 Sep; 66(6):464-8. PubMed ID: 22920414
[TBL] [Abstract][Full Text] [Related]
3. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma.
de Souza Braga M; Chaves KB; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2012 Jun; 66(4):237-41. PubMed ID: 22560459
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the NF-кB/p50/Bcl-3 complex in response to antiangiogenic therapy in a mouse model of metastatic renal cell carcinoma.
de Souza Braga M; da Silva Paiva KB; Foguer K; Barbosa Chaves KC; de Sá Lima L; Scavone C; Bellini MH
Biomed Pharmacother; 2014 Sep; 68(7):873-9. PubMed ID: 25113400
[TBL] [Abstract][Full Text] [Related]
5. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model.
Chaves KC; Peron JP; Chammas R; Turaça LT; Pesquero JB; Braga MS; Foguer K; Schor N; Bellini MH
Cancer Gene Ther; 2012 Aug; 19(8):558-65. PubMed ID: 22699868
[TBL] [Abstract][Full Text] [Related]
6. Endostatin gene therapy inhibits intratumoral macrophage M2 polarization.
Foguer K; Braga Mde S; Peron JP; Bortoluci KR; Bellini MH
Biomed Pharmacother; 2016 Apr; 79():102-11. PubMed ID: 27044818
[TBL] [Abstract][Full Text] [Related]
7. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors.
Guan X; Liu Z; Zhang J; Jin X
Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412
[TBL] [Abstract][Full Text] [Related]
9. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
Braga MS; Turaça TL; Foguer K; Chaves KC; Pesquero JB; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2013 Jul; 67(6):511-5. PubMed ID: 23726969
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
12. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
13. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
14. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
[TBL] [Abstract][Full Text] [Related]
15. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.
Flörcken A; Takvorian A; Singh A; Gerhardt A; Ostendorf BN; Dörken B; Pezzutto A; Westermann J
Immunol Lett; 2015 Dec; 168(2):260-7. PubMed ID: 26462434
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Wang HF; Ning F; Liu ZC; Wu L; Li ZQ; Qi YF; Zhang G; Wang HS; Cai SH; Du J
Cancer Immunol Immunother; 2017 Mar; 66(3):355-366. PubMed ID: 27915371
[TBL] [Abstract][Full Text] [Related]
18. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
19. Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.
Hegde VL; Singh UP; Nagarkatti PS; Nagarkatti M
J Immunol; 2015 Jun; 194(11):5211-22. PubMed ID: 25917103
[TBL] [Abstract][Full Text] [Related]
20. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Zhao Q; Guo J; Wang G; Chu Y; Hu X
Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
